Ciba Specialty Chemicals Corporation
540 White Plains Road
P.O. Box 2005
Tarrytown, NY 10591-9005
8am to 5pm Phone: (8110) 431-2380
24-Hour Health/Environmental Emergency Phone: (800) 873-1138
Effective Date: 6/15/00 Material Safety Data Sheet MSDS No: 133
|1. PRODUCT IDENTIFICATION
Trade Name: Irganox 1076
Important Use Information:
This material is not intended for use in products for which prolonged contact with mucous membranes or abraded skin, body fluids, or implantation within the human body, is specifically intended, unless the finished product has been tested in accordance with national and international applicable safety regulations. Because of the wide range of such potential uses, Ciba Specialty Chemicals Corporation is not able to recommend this material as safe and effective for such uses and assumes no liability for such uses.
2. COMPOSITION / INFORMATION ON INGREDIENTS
|CAS No.||CHEMICAL IDENTITY||EXPOSURE LIMITS||CARCINOGEN STATUS|
Common Name: Concentration
98 - 100 % by wt
3. HAZARDS IDENTIFICATION
White to off-white crystalline powder.
Use proper grounding techniques when emptying this product from containers weighing more than 1 pound. A build-up of hazardous electrostatic charges could cause a flash fire or explosion when contents are emptied into a flammable atmosphere. See Section 7.
This product is of low toxicity to aquatic organisms.
This product presents little or no immediate hazard to people if spilled or released.
Sweep or shovel spilled material and place into a sealable container. Pre-wet the material to prevent dust build-up. Dispose in accordance with local, state and federal regulations. Incineration is recommended. This product is not a hazardous waste under RCRA.
Primary Route of Entry:
This product is not expected to cause eye irritation.
This product may cause skin sensitization. Avoid skin contact.
Small amounts, if swallowed, are not expected to cause injury; avoid swallowing.
Considered to present little risk if inhaled. An Internal Exposure Limit (IEL) of 10 mg/m3 air (8-hour TWA) has been established.
Note: Refer to Section 11, Toxicological Information for details
4. FIRST AID MEASURES
First Aid for Swallowing:
If swallowed, give at least 3-4 glasses of water, but DO NOT induce vomiting. Do not give anything by mouth to an unconscious or convulsing person.
First Aid for Skin:
Following skin contact, wipe away excess material with a dry towel. Then wash affected areas with plenty of water and soap, if available, for several minutes. Remove and clean contaminated clothing and shoes before reuse. Get medical attention if irritation occurs.
First Aid for Inhalation:
If inhaled, remove from area to fresh air. Get medical attention if irritation develops, or if breathing becomes difficult.
First Aid for Eye:
Following eye contact, flush eyes with plenty of water for several minutes. Get medical attention if irritation occurs.
Note to Physician:
May aggravate pre-existing skin conditions, allergies and eczema. Treat symptomatically.
5. FIRE FIGHTING MEASURES
Flash Point: 523°F (273 °C)
Flash Point Method Used: Marcusson (open pan)
Carbon dioxide, dry chemical, foam, water mist.
The product can form an explosive dust/air mixture. Avoid dust formation and control ignition sources. Employ grounding, venting and explosion relief provisions in accord with accepted engineering practices in process operations capable of generating dust and/or static electricity.
Fire Fighting Instructions:
Use self-contained breathing apparatus.
6. ACCIDENTAL RELEASE MEASURES
Spill or Release Procedures:
Pre-wet material with water to avoid dust formation. Sweep or vacuum and place in sealable container for disposal. Wear protective equipment as specified below. Flush residue with water.
7. HANDLING AND STORAGE
Avoid contact with eyes and prolonged or repeated skin contact. Avoid continuous or repetitive breathing of dust. Good industrial engineering controls must be employed to prevent excess dusting in the work areas. Do not handle in such a manner as to cause excessive dusting. Use only with adequate ventilation. For industrial use only. Wash thoroughly after handling and before eating, drinking, or using tobacco products.
Keep container tightly closed when not in use and during transport.
- For All Packages:
DANGER! EXPLOSION RISK - Risk of explosion if an air-dust mixture forms - Avoid creating dusty conditions - Empty only into grounded containers - If container is larger than 550 US gallons (2m3) in volume, or when flammable solvents are present, the container must be inerted or the system otherwise designed to prevent or contain an explosion - seek expert advise.In addition, for products packaged in fused-lined (coated) fiber drums, fiber drums with conductive liners, steel drums, steel pails, and Ciba supplied bulk bags, the following instructions also apply:
- Always ground this package before emptying
The user is responsible for designing a system that safely handles solid additives and to ensure proper training of employees in the system's use.
9. PHYSICAL AND CHEMICAL PROPERTIES
White to off-white crystalline powder.
50 - 55°C (122 - 131 °F)
> 350° C (> 662 ° F)
- 1.02 (H20=1)
< 0.5 %
24.4 Centipoise at 70°C (158 °F)
- 2 x 10 (-9) mmHg at 20°C
5.73 for a l% suspension in Water
2082-79-3 Irganox 1076
19 % in Acetone at 20°C (68 °F)
57 % in Benzene at 20°C (68 °F)
57 % in Chloroform at 20°C (68 °F)
38 % in Ethyl acetate at 20°C (68 °F)
32 % in n-Hexane at 20°C (68 °F)
0.6 % in Methanol at 20°C (68 °F)
< 0.2 ppm in Water at 20°C (68 °F)
> 6 Log Po/w
10. STABILITY AND REACTIVITY
Incompatibility with other Materials:
Strong oxidizing agents, strong acids, strong bases
Hazardous Decomposition Products:
Thermal decomposition and burning may produce carbon monoxide, carbon dioxide and other toxic compounds.
Will not occur.
11. TOXICOLOGICAL INFORMATION
Acute Oral Toxicity:
LD50 (Hamsters) > 6,000 mg/kg
LD50 (Rats) > 10,000 mg/kg
Acute Dermal Toxicity:
LD50 (Rabbits) >2,000 mg/kg
Acute Inhalation Toxicity:
LC50 (Rats) >1.8 mg/l air for a 4-hour dust exposure with approx. 90% of particles >7 microns diameter. There were no mortalities at this concentration.
Intraperitoneal LD 50:
(Rats) >1,000 mg/kg
(Rabbits) Not an irritant
(Rabbits) Not an irritant
(Humans): In 4 separate repeat insult patch tests, a total of 4 of 158 subjects exhibited reactions indicative of sensitization. (Guinea Pigs): Mild sensitization. In this optimization test, six intradermal injections were used for the induction and an additional intradermal injection was used for the challange. Results showed 4/20 positive animals with Irganox 1076 and 1/20 animals from the control group demonstrating a positive reaction.
(Humans) Not a photo-irritant
Ames test: Non-mutagenic Dominant lethal test (mice): No evidence of a dominant lethal effect. Nucleus anamaly test: Nonmutagenic Chromosome studies on somatic cells: Non-mutagenic
2-Generation study (Rats): The test substance was fed in the diet at concentrations of 0, 500, 1,500 and 5,000 ppm. Treatment of the F0 males and females began when they were six weeks of age, and continued until all Fl litters had been weaned. Direct treatment of the Fl males and females began when they were 4 weeks of age, and continued until all F2 litters had been weaned. Findings at 5,000 ppm among adults of both generations (F0 and F1) that appeared to be treatment-related were as follows: a. Slight reductions in food consumption, weekly weight gain and weight gain of females during pregnancy. b. Statistically significant increases in liver weight and reduction in spleen weight. Histological examination of livers from Fl adult animals showed minimal centrilobular hepatocyte enlargement. c. In the F0 generation, initial litter size was reduced. Post-partum pup loss was increased and pup weight gain reduced. d. In the F1 generation initial litter size was again reduced. There was no pup loss. Pup-weight gain was slightly lower than among control animals despite the smaller litter size and hence reduced intra-litter competition. Organ weight analyses of selected Fl and F2 weanlings showed significantly increased liver weights and reduced spleen weights. Histological examination of these tissues from F2 weanlings showed no treatment-related changes. Mating performance, pregnancy rate and the duration of gestation at all three dietary concentrations were unaffected by treatment. The overall NOEL is below 500 ppm due to the increased liver weight and reductions in spleen weight reported among selected Fl and F2 weanlings of the intermediate and low dose group.
Segment II study (Rats): Test substance was administered by gavage to pregnant rats from day 6 to 15 of gestation, inclusive. The concentrations were 0, 150, 500 and 1,000 mg/kg. Bodyweight gain was slightly depressed in the 500 and 1,000 mg/kg dose levels and reduced feed intake was registered in a dose related fashion during the period of administration of the test substance. Retardation of physiological growth of the fetuses was recorded. No teratogenic effects were observed under the conditions of the experiment. The 150 mg/kg dose was considered to be the no observable effect level (NOEL).
Segment II study (Mice): Test substance was administered by gavage to pregnant mice from day 6 to 15 of gestation, inclusive. The concentrations were 150, 500 and 1,000 mg/kg. The average bodyweight gain as well as feed intake were comparable for all groups. There was no evidence of an adverse effect on the embryonic or fetal development in the mouse, except that, in the high-dose group, the average weight of the fetuses was found to be slightly but significantly increased when compared with the control. No teratogenic effects were observed under the conditions of the experiment. The NOEL was considered to be 500 mg/kg.
Subchronic Toxicity: (Dogs): In a 3-month toxicity study, Beagle dogs were fed a diet containing 0, 1,000, 3,000 and 10,000 ppm of the test substance. No
clinical symptoms or signs of systemic toxicity were observed and no deaths occurred during the experiment. Ophthalmic inspection, hearing test, food
consumption, bodyweight gain, mean food conversion, hematology, blood chemistry, gross pathology and histopathology revealed no treatment related
effects. The occasionally
elevated concentrations of serum bilirubin levels
were not accompanied by any histopathological changes in the liver. Organ
weights and ratios for the treated dogs were comparable to those of the control animals with the exception of a
slightly increased incidence of higher liver
weights and ratios in the dogs of the 3,000 and 10,000 ppm groups. The NOEL was concluded to be 1,000 ppm in the diet, corresponding to 31.5 - 34.5
(Rats): The test substance was administered to rats as an aerosol (dust) for 6 hours/day, 5 days/week for 3 weeks. The animals were exposed to mean gravimetric concentrations of 23 and 543 mg/m3. There were no reactions to treatment for any of the parameters investigated. The NOEL is greater than 543 mg/m3. air for male and female rats.
(Mice): Mice were administered 0, 5, 50, 500 ppm of the test substance in the feed, corresponding to a mean daily intake of about 56 mg/kg/day for the highest dose group for 24 months. The only difference seen was reduced survival time for the high dose animals. There was no evidence of an increased tumor incidence. The NOEL was 50 ppm.
(Rats): In a 104 week/feeding study, rats were treated with the test substance in the diet at levels of 0, 500, 1,500, 5,000 ppm. Reaction to treatment at the various dietary levels was as follows: At 5,000 ppm: a. A higher survival rate among females (Mindfully note: which means a lower survival rate for males). b. An inferior bodyweight gain and reduced food intake associated with a minor impairment in the efficiency of food utilization among females. c. Increased liver and thyroid weights in males and females and decreased adrenal weights in females. At 1,500 ppm: a. A reduction in food intake among male rats between weeks 53 and 80 and among females during the first 80 weeks of treatment. b. Decreased adrenal weight in females. At 500 ppm: A reduction in food intake among male and female rats between weeks 53 and 80. There was no evidence of an increased tumor incidence. The NOEL was concluded to be 500 ppm.
10 mg/kg of radiolabeled test substance was administered by gavage to 4 albino rats after a 12-hour fast (water permitted). The animals were then placed in metabolism cages for 168 hours and urine and feces samples were collected. Within 0-48 hours after administration about 73%n of the radioactivity was eliminated from the body. Afterwards, elimination proceeded slowly and was not fully completed at 168 hours. At that time 96% of the radioactivity was recovered (35% in the urine, 61% in the feces).
Other Toxicity Data:
4-week oral toxicity study (Young rats): Fifty young (4 week old) rats were treated by gavage with single daily doses of 0, 5, 30, 100 and 300 mg/kg of the test substance for 28 days. The liver was the target organ as indicated by a dose-dependent organ weight increase and by histopathology: at 300 mg/kg a minimal centrilobular hepatocytic hypertrophy was observed. A small number of high dose animals showed clinical chemistry changes, including elevated transaminase activities and cholesterol levels compared to control animals. The NOEL was considered to be 30 mg/kg/day.
12. ECOLOGICAL INFORMATION
Acute Toxicity to Fish:
Rainbow trout, 96-hour, LC50: > 100 ppm Bluegill, 96-hour, LC50: > 100 ppm
Acute Toxicity to Invertebrates:
(Daphnia magna), 24-hour, EC50: > 100 ppm
Acute Toxicity to Algae:
Green algae, 0-72 hours, EC50: > 30 ppm
Toxicity to Sewage Bacteria:
Inhibitory concentration on respiration of aerobic waste water bacteria: IC20, IC50, IC80 > 100 ppm
Combined Zahn-Wellens/carbon dioxide evolution test: Inherently biodegradable with 21 - 47% in 35 days Sturm test: Partially biodegradable
Chemical Oxygen Demand:
2.52 g COD/g
13. DISPOSAL CONSIDERATIONS
Incinerate in a chemical incinerator equipped with an after-burner and scrubber. Follow all federal, state and local regulations.
14. TRANSPORT INFORMATION
This product is not regulated by any means of transport.
15. REGULATORY INFORMATION
Chemical Weapons Convention (CWC):
This product does not contain any chemicals listed under the Chemical Weapons Convention Schedule of Chemicals.
US Federal Regulations:
Clean Air Act -Hazardous Air Pollutants (HAP):
This product contains no hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act.
Clean Air Act - Ozone Depleting Substances (ODS):
This product neither contains, nor was manufactured with, a Class I or Class II ozone depleting substance (ODS). We have relied on our suppliers labeling their products. None have done so.
Clean Water Act - Priority Pollutants (PP):
This product contains no chemicals listed under the U.S. Clean Water Act Priority Pollutant List.
FDA: Food Packaging Status
This product has been cleared by the FDA for use in food packaging and/or other applications as an indirect food additive. Call or write for specific information.
Occupational Safety and Health Act (OSHA):
This product is considered to be a hazardous chemical under the OSHA Hazard Communication Standard (29 CFR 1910.1200). Its hazards are: Immediate (acute) health hazard Fire; Sudden release of pressure (explosion) hazard.
Resource Conservation and Recovery Act (RCRA):
This product is not considered to be a P or U listed hazardous waste under RCRA (40 CFR 261).
SARA Title III: Section 302 - Extremely Hazardous Substances (EHS):
This product contains no chemicals regulated under Section 302 as extremely hazardous substances.
SARA Title III: Section 304 - CERCLA:
This product contains no chemicals regulated under Section 304 as extremely hazardous chemicals for emergency release notification ("CERCLA" List).
SARA Title III: Section 311/312 - Hazard Communication Standard (HCS):
This product is regulated under Section 311-312 (40 CFR 370).
SARA Title III: Section 313 Toxic Chemical List (TCL):
This product does not contain a toxic chemical for routine annual Toxic Chemical Release Reporting' under Sec. 313 (40 CFR 372).
TSCA Section 5(e) - Consent Order / SNUR:
This product is not subject to a Section 5(e) Consent Order or Significant New Use Rule (SNUR).
TSCA Section 8(b) - Inventory Status:
All chemical(s) comprising this product are listed on the TSCA inventory.
TSCA Section 12(h) - Export Notification:
This product does not contain any chemicals subject to Section 12(b) export notification.
Additional Federal Information:
This product is not subject to a Section 5(t)/6(a) rule.
Australian Inventory Status:
This product contains only chemicals which are currently listed on the Australian Inventory of Chemical Substances.
Canadian Inventory Status:
This product contains only chemicals which are currently listed on the Canadian Domestic Substance List.
European Inventory Status (EINECS):
This product contains only chemicals which are currently listed on the European Inventory of Existing Commercial Chemical Substances (EINECS).
Korean Inventory Status:
This product contains only chemicals which are currently listed on the Korean Chemical Substances List.
Japanese Inventory Status:
This product contains only chemicals currently listed on the Japanese Ministry of International Trade and Industry List of Existing and New Chemical Substances. The MITI registration number(s) are: (3)-1737
Additional International Information:
This product contains only chemicals which are currently listed on the Philippine Inventory of Chemical Substances.
California Proposition 65:
This product does not contain any chemicals currently on the California list of Known Carcinogens and Reproductive Toxins.
This product does not contain any chemicals which are subject to Massachusetts Right-to-Know disclosure requirement.
New Jersey Right-to-Know:
The following is required composition information:
Chemical Name: Octadecyl 3,5-Di-(tert)-butyl-4-hydroxyhydrocinnamate Common Name: Irganox 1076 CASRN: 2082-79-3
The following is required composition information:
Chemical Name: Octadecyl 3,5-Di-(tert)-butyl-4-hydroxyhydrocinnamate
Common Name: Irganox 1076 CASRN: 2082-79-3
Comment: Not on Pennsylvania Hazardous Substance List
16. OTHER INFORMATION
MSDS No: 133
The information and recommendations contained herein are based upon data believed to be correct. However, no guarantee or warranty of any kind expressed or implied is made with respect to the information contained herein.
For technical information contact your technical sales representative. For additional health / safety / regulatory information, contact the Product Safety Customer Coordinator at (914) 785-4288.
If you have come to this page from an outside location click here to get back to mindfully.org